Education
About Us
Working with TipRanks
Follow Us
X4 Pharmaceuticals Inc (XFOR)
NASDAQ:XFOR
Top Page
X4 Pharmaceuticals
(NASDAQ:XFOR)
Select Model
Select Model
Rating:48Neutral
Price Target:
$3.50
▼(-17.26% Downside)
Action:ReiteratedDate:03/17/26
The score is held back primarily by weak financial performance (large losses and persistent cash burn), partially offset by a materially de-risked balance sheet and strong 2025 revenue growth. Technicals are mixed and valuation support is limited due to negative earnings.
Positive Factors
Regulatory Approval Progress
A CHMP positive opinion materially de-risks EU commercialization for mavorixafor, potentially making it the first available therapy for WHIM syndrome in Europe. That structural regulatory progress raises the probability of a sustained revenue stream and supports long-term market access planning.
Strong Liquidity / Runway
A ~$253M cash position and multi-year runway materially reduces near-term financing risk and allows the company to fund pivotal trials and initial commercialization activities. This liquidity supports execution of strategic plans and provides time to reach revenue inflection points without urgent dilutive financing.
Revenue Step-Up and Gross Margins
A large revenue step-up and strong gross profit suggest early commercial traction or milestone-driven income that can scale. Durable higher top-line and healthy product-level margins improve the path to unit economics and indicate the business can generate meaningful revenue as approvals and launch activities proceed.
Negative Factors
Persistent Cash Burn
Sustained negative operating and free cash flow implies the business still consumes significant capital to run trials and commercial activities. Over the medium term this raises funding dependency and execution risk if commercialization or trial timelines slip, despite the current runway.
Substantial Operating Losses
Large ongoing operating and net losses indicate the company remains far from break-even, limiting internal reinvestment capacity and pressuring equity economics. Persistent losses can constrain strategic flexibility and mean long-term value depends on successful commercialization or approval milestones.
Clinical-stage, Single-Asset Concentration
Dependence on a single lead product in clinical and early commercialization stages concentrates binary trial and regulatory risk. Even with EU progress, setbacks in pivotal trials, label scope, or launch execution could materially impair revenue prospects and growth durability over the medium term.
X4 Pharmaceuticals (XFOR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$369.86M
Dividend YieldN/A
Average Volume (3M)577.00K
Price to Earnings (P/E)―
Beta (1Y)1.30
Revenue Growth2925.73%
EPS Growth-294.29%
CountryUS
Employees143
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.22
Shares Outstanding87,436,690
10 Day Avg. Volume650,157
30 Day Avg. Volume577,000
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.91
Price to Sales (P/S)4.82
P/FCF Ratio-1.98
Enterprise Value/Market Cap-0.46
Enterprise Value/Revenue-5.01
Enterprise Value/Gross Profit-6.02
Enterprise Value/Ebitda2.02
Forecast
1Y Price Target
$12.00Price Target Upside183.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.99
Revenue Forecast (FY)$10.13M
X4 Pharmaceuticals Business Overview & Revenue Model
Company DescriptionX4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
How the Company Makes Moneynull
X4 Pharmaceuticals Earnings Call Summary
Earnings Call Date:May 01, 2025
(Q1-2025)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in clinical trials and global expansion efforts, supported by a strong financial position and promising market research. However, challenges remain in sales consistency and the brief commercial history in the WHIM market.Q1-2025 Updates
Positive Updates
Clinical Trial Advancements
X4 advanced the 4WARD Phase III trial for chronic neutropenia (CN), with over 90% of global trial sites activated and a finalized trial design based on regulatory feedback.
US Patent Allowance
Received a notice of allowance from the US patent office for using mavorixafor to treat severe chronic idiopathic and autoimmune neutropenia, with an expiration date in March 2041.
Global Expansion Efforts
Mavorixafor's MAA was accepted by European authorities, with potential EMA approval expected by Q1 2026. New partnerships established for commercialization in Europe, Australia, New Zealand, and the MENA region.
Financial Position
Ended Q1 2025 with nearly $90 million in cash and equivalents, with sufficient funds to support operations into the first half of 2026.
Positive Market Research for CN
Completed a survey with 95 US physicians, revealing higher case loads and a clear unmet need in the CN market.
Negative Updates
Sales Fluctuations
Quarterly sales of XOLREMDI were slightly lower than the previous quarter due to inventory resupply timing and market lumpiness.
Challenges in WHIM Syndrome Market
Despite progress, the commercial history in the WHIM market is still brief, leading to challenges in establishing stable sales patterns.
Company Guidance
During the X4 Pharmaceuticals Q1 2025 financial call, the company provided several key metrics and updates. The 4WARD trial, a pivotal Phase III study for mavorixafor in chronic neutropenia (CN), is actively enrolling participants with over 90% of global trial sites activated. The trial aims to demonstrate statistically significant improvements in absolute neutrophil count (ANC) response and reductions in annualized infection rates, targeting a CN population of about 15,000 in the US with high unmet medical needs. The trial is powered at over 95% for the ANC endpoint and over 90% for infection rate outcomes. X4 anticipates full enrollment by Q3 or Q4 2025, with top-line data expected in H2 2026. Financially, X4 reported ending Q1 with just under $90 million in cash, with cumulative XOLREMDI sales reaching $3.5 million since its May 2024 launch. Additionally, the company highlighted its strategic partnerships for expanding mavorixafor's reach globally, including expected EMA approval by Q1 2026.X4 Pharmaceuticals Financial Statement Overview
Summary
Despite a major revenue step-up in 2025 and a much improved balance sheet (debt reduced sharply and equity higher), profitability and cash generation remain weak with large operating losses and continued heavy negative operating/free cash flow.Income Statement
The company shows a sharp step-up in scale in 2025 (annual revenue rose to ~$35.1M vs. ~$2.6M in 2024), and gross profit is strong relative to revenue (2025 gross profit of ~$29.4M). However, profitability remains weak with sizable operating losses (2025 EBIT of about -$86.9M) and a large net loss (about -$79.2M). Overall, revenue momentum is improving, but losses are still substantial and indicate a business not yet near breakeven.34
Negative
Balance Sheet
Leverage improved dramatically in 2025, with total debt falling to about $1.0M and equity rising to about $186.3M, supported by a larger asset base (~$290.5M). This is a major turnaround from 2024, when debt was high (~$78.1M) and debt was more than 3x equity. The key weakness is that equity quality is pressured by persistent losses (negative returns on equity in prior years), but the current capital structure appears materially de-risked versus recent history.66
Positive
Cash Flow
Cash generation remains a central concern: operating cash flow and free cash flow are consistently negative across the period, including 2025 operating/free cash flow around -$85.6M. While the burn improved versus 2024 (operating cash flow around -$130.9M), free cash flow growth in 2025 is still negative, indicating ongoing cash consumption. The company’s operating profile is still reliant on funding rather than self-sustaining cash flows.30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.98M | 35.11M | 2.56M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 28.28M | 29.36M | 1.76M | 0.00 | 0.00 | -1.89M |
| EBITDA | -84.47M | -86.88M | -27.58M | -94.89M | -89.33M | -84.54M |
| Net Income | -95.09M | -79.20M | -37.45M | -101.17M | -93.87M | -88.70M |
Balance Sheet | ||||||
| Total Assets | 163.56M | 290.46M | 146.45M | 147.26M | 155.59M | 117.18M |
| Cash, Cash Equivalents and Short-Term Investments | 122.42M | 253.00M | 102.06M | 114.22M | 121.72M | 81.79M |
| Total Debt | 77.36M | 994.00K | 78.09M | 58.28M | 38.42M | 39.78M |
| Total Liabilities | 101.94M | 104.17M | 124.30M | 96.16M | 81.53M | 52.76M |
| Stockholders Equity | 61.62M | 186.29M | 22.15M | 51.10M | 74.05M | 64.41M |
Cash Flow | ||||||
| Free Cash Flow | -106.13M | -85.62M | -131.23M | -96.57M | -77.20M | -71.52M |
| Operating Cash Flow | -103.09M | -85.62M | -130.90M | -96.51M | -77.10M | -70.91M |
| Investing Cash Flow | -17.32M | 8.15M | 66.99M | -14.88M | -103.00K | -615.00K |
| Financing Cash Flow | 92.67M | 238.63M | 20.29M | 88.52M | 117.23M | 74.25M |
X4 Pharmaceuticals Technical Analysis
Positive
4.23
Price Trends
3.68
Positive
3.73
Positive
3.25
Positive
Market Momentum
0.13
Negative
55.30
Neutral
38.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XFOR, the sentiment is Positive. The current price of 4.23 is above the 20-day moving average (MA) of 3.66, above the 50-day MA of 3.68, and above the 200-day MA of 3.25, indicating a bullish trend. The MACD of 0.13 indicates Negative momentum. The RSI at 55.30 is Neutral, neither overbought nor oversold. The STOCH value of 38.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XFOR.
X4 Pharmaceuticals Risk Analysis
X4 Pharmaceuticals disclosed 69 risk factors in its most recent earnings report. X4 Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
X4 Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $248.83M | -6.26 | -236.85% | ― | -8.64% | 85.68% | |
53 Neutral | $83.19M | ― | -59.07% | ― | ― | -58.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $130.92M | -3.02 | -148.81% | ― | -90.43% | -382.07% | |
48 Neutral | $369.86M | -2.14 | -138.41% | ― | 2925.73% | -294.29% | |
46 Neutral | $62.15M | -3.11 | 138.71% | ― | ― | -9.32% |
* Healthcare Sector Average
XFOR
X4 Pharmaceuticals
4.05
-4.94
-54.95%
CBUS
Cibus
2.77
0.40
16.88%
NRXP
NRX Pharmaceuticals
1.90
-0.28
-12.84%
EQ
Equillium
2.13
1.32
162.96%
PMVP
PMV Pharmaceuticals
1.49
0.21
16.41%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.